AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Zinc phosphodiesterase ELAC protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BQ52

UPID:

RNZ2_HUMAN

Alternative names:

ElaC homolog protein 2; Heredity prostate cancer protein 2; Ribonuclease Z 2; tRNA 3 endonuclease 2; tRNase Z 2

Alternative UPACC:

Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1

Background:

Zinc phosphodiesterase ELAC protein 2, also known as Heredity prostate cancer protein 2, plays a crucial role in mitochondrial tRNA maturation. It is involved in removing a 3'-trailer from precursor tRNA, essential for RNA processing and ribosome assembly. This protein is associated with mitochondrial DNA complexes, initiating crucial cellular processes.

Therapeutic significance:

ELAC2 is linked to hereditary prostate cancer and combined oxidative phosphorylation deficiency 17, highlighting its importance in disease mechanisms. Understanding the role of ELAC2 could lead to novel therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.